306 related articles for article (PubMed ID: 3974201)
1. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
2. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of newly induced murine sarcomas.
Shu SY; Rosenberg SA
Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of host resistance against tumors by glycyrrhizin, an active component of licorice roots.
Suzuki F; Schmitt DA; Utsunomiya T; Pollard RB
In Vivo; 1992; 6(6):589-96. PubMed ID: 1296807
[TBL] [Abstract][Full Text] [Related]
5. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
6. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
Chou T; Shu S
J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Shu S; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors.
Awwad M; North RJ
Cancer Res; 1990 Apr; 50(8):2228-33. PubMed ID: 2317810
[TBL] [Abstract][Full Text] [Related]
9. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
10. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
11. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Shu S; Chou T; Rosenberg SA
Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
[TBL] [Abstract][Full Text] [Related]
12. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
13. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
[TBL] [Abstract][Full Text] [Related]
14. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik M; Dougherty GJ
Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
[TBL] [Abstract][Full Text] [Related]
16. Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2.
Greenberg PD; Cheever MA
J Biol Response Mod; 1984 Oct; 3(5):455-61. PubMed ID: 6239012
[TBL] [Abstract][Full Text] [Related]
17. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.
Greenberg PD; Cheever MA
J Immunol; 1984 Dec; 133(6):3401-7. PubMed ID: 6149246
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor effect of a novel antitumor compound, NC-190, in the double grafted tumor system].
Ebina T; Shishido K; Murata K
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1345-50. PubMed ID: 2369138
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor effect of Cepharanthin in the double grafted tumor system].
Ebina T; Ishikawa K; Murata K
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1165-71. PubMed ID: 2350192
[TBL] [Abstract][Full Text] [Related]
20. In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo.
Forni G; Giovarelli M
J Immunol; 1984 Jan; 132(1):527-33. PubMed ID: 6228583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
